EUVIMEDEUVIMED entdecken
Crossref

Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability

Shivahamy Maheswaran, Aylin S Dedeoglu, Andrzej Niemierko, Rachel O Abelman, Rachel Jimenez, Olivia Rieur, Jennifer Hutchinson, Neelima Vidula, Laura M Spring, Leif W Ellisen, Steven J Isakoff, Seth A Wander und 2 weitere

Breast Cancer Research and Treatment · 2026

DOI: 10.1007/s10549-026-08079-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Shivahamy Maheswaran und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Biomarkers, Tumor, Antibodies, Monoclonal, Humanized, Camptothecin. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Optimizing metaplastic breast cancer (MpBC) management remains an unmet clinical need. Current literature on MpBC response toantibody drug-conjugates is limited to individual case reports and case series. This study investigates outcomes in metastatic MpBC treated withsacituzumab govitecan (SG) and characterizes actionable targets to inform future studies. METHODS: Patients (pts) with metastatic triple negative breastcancer (TNBC) treated at the Massachusetts General Hospital Cancer Center between 2000 and 2025 were assessed for MpBC and receipt of SG. MpBCcases were interrogated for biomarkers qualifying for targeted therapy: HER2-low status (IHC 1+/2+), combined positive score (CPS), and targetablegenomic variants based on next-generation sequencing of plasma and/or tissue ordered by the treating provider. Multivariable Cox regression analysisassessed the association of MpBC under SG treatment with progression-free survival (PFS) and overall survival. RESULTS: MpBC cases (n = 17) had anumerically shorter median PFS under SG compared to non-MpBC TNBC (n = 133) [2.6 vs. 6.8 months, p = 0.16]. While most patients with MpBC hadlimited response to SG monotherapy, two patients on SG + talazoparib had prolonged PFS. Annotation of available genomic and pathology data from allpatients with MpBC (n = 58) revealed targetable alterations including 34/56 patients with HER2-low status, 8/45 patients with germline BRCA1/2mut, and9/30 patients with somatic PIK3CAmut. MpBC response to matched therapies showed variable PFS. CONCLUSION: To our knowledge, this study is one ofthe largest analyses of MpBC response to SG and highlights challenges of treating rare diseases at large. Multi-institutional collaboration and inclusive trialdesign are essential to optimize treatments for MpBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsBiomarkers, TumorAntibodies, Monoclonal, HumanizedCamptothecinHumansFemaleMiddle AgedAgedAdultNeoplasm MetastasisTreatment OutcomeErb-b2 Receptor Tyrosine KinasesMetaplasiaMolecular Targeted TherapyImmunoconjugates

Stichwörter der Autor:innen

Antibody–drug conjugatesGenomic profilingMetaplastic breast cancerSacituzumab govitecanTriple-negative breast cancer

Substanzen

Biomarkers, Tumorsacituzumab govitecanAntibodies, Monoclonal, HumanizedCamptothecinErb-b2 Receptor Tyrosine KinasesImmunoconjugates

Autor:innen und Institutionen

  • Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
  • Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA. amedford@mgh.harvard.edu.

Zitieren

APA

Maheswaran, S., Dedeoglu, A. S., Niemierko, A., Abelman, R. O., Jimenez, R., Rieur, O., Hutchinson, J., Vidula, N., Spring, L. M., Ellisen, L. W., Isakoff, S. J., Wander, S. A., Bardia, A., & Medford, A. J. (2026). Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08079-0

Vancouver

Maheswaran S, Dedeoglu AS, Niemierko A, Abelman RO, Jimenez R, Rieur O, et al. Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08079-0

BibTeX
@article{Maheswaran2026,
  author = {Maheswaran, Shivahamy and Dedeoglu, Aylin S and Niemierko, Andrzej and Abelman, Rachel O and Jimenez, Rachel and Rieur, Olivia and Hutchinson, Jennifer and Vidula, Neelima and Spring, Laura M and Ellisen, Leif W and Isakoff, Steven J and Wander, Seth A and Bardia, Aditya and Medford, Arielle J},
  title = {Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  doi = {10.1007/s10549-026-08079-0}
}
Kostenlos starten →